<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820780</url>
  </required_header>
  <id_info>
    <org_study_id>P110128</org_study_id>
    <nct_id>NCT01820780</nct_id>
  </id_info>
  <brief_title>Early Care After Discharge of HF Patients</brief_title>
  <acronym>ECAD-HF</acronym>
  <official_title>Usefulness of a Short-time But Very Early Specialized Follow-up After Hospitalization for Acute Heart Failure: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After decompensated heart failure, a number of patients have high risk of early
      rehospitalization as well as death. Specialized medical management for a short period but
      very early after discharge could be critical for optimizing care and improving early outcome.

      This study aims to compare such early intensive medical management with usual care in
      high-risk patients after discharge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At discharge, high-risk HF patients are selected and randomized in two groups:

        -  Control group: usual disease management according to guidelines and including first
           medical consultation and biological test within the 4-week time following discharge.

        -  Active group: consultations with HF specialist including biological test at weeks 1, 2
           and 4 are planned in addition to usual management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2013</start_date>
  <completion_date type="Anticipated">June 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with all cause death or unplanned hospitalization at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality at 12 months</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned HF-related hospitalization at 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of alive and hospitalization-free days at 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and distribution modified Goldman classe at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natriuretic peptides blood levels at 6 months.</measure>
    <time_frame>6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global cost of patient management</measure>
    <time_frame>from day0 to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF-treatment at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and distribution NYHA classe at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of subgroups (LVEF altered or not, first HF episode or not, age&gt; or ≤ 75, Changes in levels of BNP or NT-proBNP between day0 and the second consultation in the active group: ≥ 30% decrease, ≥ 30% increase, Intermediate variation).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers measured in plasma collected at day0: predictive value of the risk of death and hospitalization during the period of 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">534</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>intensive disease management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual disease management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natriuretic peptides levels to J7 and J14</intervention_name>
    <arm_group_label>intensive disease management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Consultations specialized to J7 and J14</intervention_name>
    <description>Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage</description>
    <arm_group_label>intensive disease management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phone calls in 6 months and 12 months</intervention_name>
    <arm_group_label>intensive disease management</arm_group_label>
    <arm_group_label>usual disease management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natriuretic peptides levels at 6 months</intervention_name>
    <arm_group_label>intensive disease management</arm_group_label>
    <arm_group_label>usual disease management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Consultation with the general doctor or the cardiologist to J30 with blood results</intervention_name>
    <arm_group_label>intensive disease management</arm_group_label>
    <arm_group_label>usual disease management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or more

          -  consent signed

          -  Acute or decompensated heart failure with one or more of following criteria at
             discharge:

          -  BNP &gt; 350 pg/ml or NTproBNP &gt; 2200 pg/ml

          -  Serum creatinine ≥ 180µM

          -  Systolic blood pressure ≤ 110mmHg

        Exclusion Criteria:

          -  acute coronary syndrome,

          -  acute myocarditis,

          -  isolated right HF,

          -  transient HF,

          -  planned cardiac surgery,

          -  high risk of short-term non-cardiac death,

          -  planned management within rehabilitation center/HF clinic at discharge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOGEART Damien, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lariboisiere Hospital, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LOGEART Damien, MD, PhD</last_name>
    <phone>+33149958674</phone>
    <email>damien.logeart@lrb.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Cardiologie - Hopital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien LOGEART, MD, PhD</last_name>
      <phone>+33149958674</phone>
      <email>damien.logeart@lrb.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Disease management program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

